Neurogene Completes Enrollment in Embolden Trial of NGN-401
MT Newswires Live
Jun 08
Neurogene (NGNE) has completed dosing in the Embolden registrational trial of NGN-401 for Rett syndrome, exceeding its initial target by enrolling 25 participants, the company said Monday.
Neurogene said the trial was overenrolled due to strong demand from the Rett syndrome community and that NGN-401 at the 1E15 vg dose has been generally well tolerated, with no cases of hemophagocytic
lymphohistiocytosis reported.
The company said topline data from the Embolden trial are expected in the second half of next year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.